Combination Antibacterial Composition and Short-Course Antibacterial Regimen
AssigneeGlobal Alliance for TB Drug Development
InventorsKhisimuzi Mdluli, JR., Cari M. Mendel, Eric Nuermberger
Life of this patent
Estimating the term…
Abstract
The present invention relates to therapeutic combinations of anti-bacterial agents linezolid, bedaquiline and pretomanid, and optionally with pyrazinamide, in a short-course oral dosage regimen for the treatment of tuberculosis.
Claims30
1-16. (canceled)
A method for the treatment of tuberculosis, comprising the step of administering to a patient in need thereof therapeutically effective amounts of anti-bacterial agents, wherein the anti-bacterial agents consist of linezolid, bedaquiline and pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof,
- wherein the linezolid is administered for a first period of time,
- wherein the bedaquiline and pretomanid are administered for a second period of time, and
- wherein the first period of time is shorter than the second period of time, and
- wherein the first period of time is one to two months.
The method according to claim 32, wherein linezolid is administered for two months.
A method for the treatment of extensively drug-resistant (XDR) tuberculosis, comprising the step of administering to a patient in need thereof therapeutically effective amounts of anti-bacterial agents, wherein the anti-bacterial agents consist of linezolid, bedaquiline, and pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof,
- wherein linezolid is re-administered after a one to two week drug holiday.
A method for the treatment of multidrug-resistant (MDR) tuberculosis, comprising the step of administering to a patient in need thereof therapeutically effective amounts of anti-bacterial agents, wherein the anti-bacterial agents consist of linezolid, bedaquiline and pretomanid, and optionally pyrazinamide, or a pharmaceutically acceptable salt of each thereof,
- wherein linezolid is re-administered after a one to two week drug holiday.
Dependencies are inferred from the claim text.